Mg. Murphy et al., THE GASTRIN-RECEPTOR ANTAGONIST L-365,260 INHIBITS STIMULATED ACID-SECRETION IN HUMANS, Clinical pharmacology and therapeutics, 54(5), 1993, pp. 533-539
We investigated the effect of a novel gastrin-cholecystokinin-B recept
or antagonist, L-365,260 -1,3-dihydro-5-phenyl-2H-1,4-benzodiazepin-2-
one], on gastric acid secretion in humans. In a double-blind, four-per
iod crossover study, eight subjects received single oral doses of plac
ebo or of 2.5, 10, or 50 mg L-365,260, followed by an intravenous infu
sion of pentagastrin at doses of 0.05, 0.4, and 2 mug/kg/hr for succes
sive 30-minute periods. L-365,260 caused a dose-dependent inhibition o
f pentagastrin-stimulated gastric acid secretion. A single oral dose o
f 50 mg L-365,260 produced 50% inhibition of the gastric acid output r
esponse to pentagastrin (0.4 mug/kg/hr) when the mean (+/- SD) plasma
L-365,260 concentration was 502 +/- 108 ng/ml. Plasma L-365,260 concen
trations (all doses combined) and the inhibition of gastric acid outpu
t were correlated with a correlation coefficient of r = 0.45 (p < 0.05
). Single oral doses of L-365,260 up to 50 mg did not inhibit basal ga
stric acid output or alter plasma gastrin concentrations. L-365,260 wa
s well tolerated at oral doses up to 50 mg. These findings show that L
-365,260 is an orally active antagonist at gastrin-cholecystokinin-B r
eceptors in humans.